Clinical trials / NCT02132741
Recruiting

Optical Coherence Tomography And NEphropathy: The OCTANE Study

Patients with high blood pressure (hypertension) and chronic kidney disease are at an increased risk of developing heart disease and strokes. Part of this risk is due to changes in the structure and function of the blood vessels throughout the body. It is thought that reducing high blood pressure and treating chronic kidney disease improves the structure and function of blood vessels but information on this is limited. Optical coherence tomography (OCT) is a method of looking at the blood vessels at the back of…

ClinicalTrials.gov IDNCT02132741
PhaseNot Applicable
Enrollment150
SponsorUniversity of Edinburgh
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Health, Hypertension, Chronic Kidney Disease

About this study

Patients with high blood pressure (hypertension) and chronic kidney disease are at an increased risk of developing heart disease and strokes. Part of this risk is due to changes in the structure and function of the blood vessels throughout the body. It is thought that reducing high blood pressure and treating chronic kidney disease improves the structure and function of blood vessels but information on this is limited. Optical coherence tomography (OCT) is a method of looking at the blood vessels at the back of the eye. It is a simple, quick and non-invasive test that you may have previously had during a visit to the optician. The purpose of the study is to ascertain whether OCT is able to detect changes in the eye's blood vessels in patients with hypertension and chronic kidney disease compared to healthy individuals and also to see if any differences seen improve with treatment.

Primary outcomes

Eligibility information

Inclusion Criteria: * Male or female * Age 18-80 * Body mass index ≤35 * For those with hypertension: BP ≥140/90 or on treatment for hypertension * For those with CKD: CKD as defined by the Kidney Diseases Quality Initiative guidelines Exclusion Criteria: * Subject is below the age of legal consent, or is mentally or legally incapacitated * The subject has donated blood (450 ml) within the last 4 weeks * Past or present drug or alcohol abuse including intravenous drug abuse at any time * Participation in another clinical trial within 1 month * Considered to be at high risk of HIV or hepatitis B * Patients with known eye disease, or previous eye surgery, or refractive error greater than +/- 6 dioptres.

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.